নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 0.2mg equivalent to 0.178 mg free base - tablet - 0.2 mg - active: desmopressin acetate trihydrate 0.2mg equivalent to 0.178 mg free base excipient: lactose monohydrate magnesium stearate potato starch povidone

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - phosphoric acid 548.22 mg/ml (75%w/w. ho4p2na12h2o & h2o4pna2h2o produced from naoh & phoshoric acid in solution);  ; sodium hydroxide 379.33 mg/ml (50%w/w. in solution quantities 240 mg/ml ho4p2na12h2o & 542 mg/ml h2o4pna2h2o);   - oral solution - active: phosphoric acid 548.22 mg/ml (75%w/w. ho4p2na12h2o & h2o4pna2h2o produced from naoh & phoshoric acid in solution)   sodium hydroxide 379.33 mg/ml (50%w/w. in solution quantities 240 mg/ml ho4p2na12h2o & 542 mg/ml h2o4pna2h2o)   excipient: ginger flavour 5741 glycerol purified water saccharin sodium sodium benzoate - for use as part of a bowel cleansing regimen in preparing adult patients from 18 years for colon surgery or for preparing the colon for x-ray or endoscopic examination.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 0.1 mg/ml equivalent to 0.089 mg desmopressin free base - nasal spray solution - 0.1 mg/ml - active: desmopressin acetate trihydrate 0.1 mg/ml equivalent to 0.089 mg desmopressin free base excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate dihydrate sodium chloride water for injection

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - homatropine hydrobromide 2%;  ; polysorbate 80 0.01% - eye drops, solution - 2 % - active: homatropine hydrobromide 2%   polysorbate 80 0.01% excipient: benzalkonium chloride as 50% solution. hydrochloric acid hypromellose purified water sodium chloride

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - ganciclovir sodium 543mg equivalent to 500 mg ganciclovir - powder for infusion - 500 mg - active: ganciclovir sodium 543mg equivalent to 500 mg ganciclovir - iindicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - albumin 200 g/l (albumin ex nz) - solution for infusion - 20% w/v - active: albumin 200 g/l (albumin ex nz) excipient: octanoate ions sodium water for injection - hypoproteinaemia in the acutely ill patient; albumex® 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - albumin 40 g/l (albumin ex nz) - solution for infusion - 4% w/v - active: albumin 40 g/l (albumin ex nz) excipient: octanoate ions sodium water for injection - hypovolaemia/shock; preservation of an adequate circulating blood volume should be the primary aim of therapy. albumex® 4 may be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25 g/litre), or if it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex® 4 may also be useful following initial resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) - solution for injection - 400 iu - active: hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - immunoglobulin g 160 mg/ml (immunoglobulin ex nz 16% igg) - solution for injection - 160 mg/ml - active: immunoglobulin g 160 mg/ml (immunoglobulin ex nz 16% igg) excipient: glycine - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - tetanus immunoglobulin, human 250 [iu] (immunoglobulin ex nz =160mg/ml) - solution for injection - 250 iu - active: tetanus immunoglobulin, human 250 [iu] (immunoglobulin ex nz =160mg/ml) excipient: glycine - tetanus immunoglobulin-vf is indicated for the passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. it should also be given to the fully immunised patient with a tetanus-prone wound if more than 10 years have elapsed since the last vaccine dose. in all the above instances, active immunisation with a tetanus vaccine should be commenced at the same time according to current datasheet recommendations.